Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses
Authors:
- Joanne ShawJSJoanne Shaw
- Shahram MoriSMShahram Mori
- Cherylyn A SavaryCSCherylyn A Savary
- Craig A MullenCMCraig A Mullen
- 1 April 2005
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 46 (4) , 571-580
Abstract
In allogeneic hematopoietic stem cell (HSC) transplantation, graft vs. tumor (GVT) activity contributes to the cancer cure. It is closely associated with graft vs. host disease (GVHD), an immune response initiated by transplanted donor T-cell responses against host minor histocompatibility antigens (mHAgs). GVHD is prevented by T-cell depletion of the donor graft, but T-cell depletion also abrogates curative GVT. We wished to test the hypothesis that cellular tumor vaccines administered after T cell-depleted HSC transplant can induce significant GVT effects, despite the absence of transplanted mature donor T cells. In this investigation, a murine model of major histocompatibility complex (MHC)-matched, mHAg-mismatched allogeneic HSC transplant was studied. T cell-depleted or normal T cell-containing grafts were given to myeloablated recipients. Following reconstitution the recipients were vaccinated with tumor vaccines. GVT responses were measured in vitro by T-cell function assays and flow cytometry, and in vivo by tumor burden or survival. Post-transplant tumor vaccines induced effective anti-tumor responses in recipients of T cell-depleted transplants, producing cytolytic and cytokine responses, reduced tumor burden and prolonged survival. Recipients of T cell-depleted transplants that still have significant thymic function may be suitable subjects for post-transplant vaccine therapy.Keywords
This publication has 18 references indexed in Scilit:
- Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graftBone Marrow Transplantation, 2003
- In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigensNature Medicine, 2002
- Rapid titer determination using quantitative real-time PCRGene Therapy, 1999
- Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donorsBone Marrow Transplantation, 1998
- Rapid Communication: Increased Frequency of TCRγδ+ T Cells in Disease-Free Survivors Following T Cell-Depleted, Partially Mismatched, Related Donor Bone Marrow Transplantation for Leukemia1996
- Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.Journal of Clinical Investigation, 1996
- Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxisThe Lancet, 1995
- HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptidesNature, 1992
- Graft-versus-Host Disease as Adoptive Immunotherapy in Patients with Advanced Hematologic NeoplasmsNew England Journal of Medicine, 1989
- Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice.Journal of Experimental Medicine, 1987